Key points are not available for this paper at this time.
Previous clinical trials presented efficacy and safety of Janus kinase 1 inhibitor upadacitinib through 52 weeks for moderate-to-severe atopic dermatitis (AD).
Hagino et al. (Tue,) studied this question.